Moderna, Inc.: Influenza, Human trials

The registry lists 23 Influenza, Human studies with Moderna, Inc. as lead sponsor. 2 are open to participants now and 12 have results posted.

Phase 1 11Phase 2 10Phase 3 7Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Updated mRNA Seasonal Influenza VaccinesNot yet recruitingNCT07884175Phase 4
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenNot yet recruitingNCT07870330Phase 1
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeCompletedNCT06602024Phase 3Results posted
• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)CompletedNCT06508320Phase 2Results posted
• A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeCompletedNCT06097273Phase 3Results posted
• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy AdultsCompletedNCT05868382Phase 2Results posted
• Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedNCT05827978Phase 3Results posted
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsCompletedNCT05827926Phase 1/2Results posted
• A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy AdultsCompletedNCT05827068Phase 1/2Results posted
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderCompletedNCT05566639Phase 3Results posted
• A Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedNCT05415462Phase 3Results posted
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldCompletedNCT05375838Phase 1/2Results posted
• A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy AdultsCompletedNCT05333289Phase 1/2Results posted
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy AdultsCompletedNCT04956575Phase 1/2Results posted
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 3
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeCompletedNCT06864143Phase 2
• Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeCompletedNCT06694389Phase 3
• A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsCompletedNCT05972174Phase 1/2
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsCompletedNCT05606965Phase 2
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedNCT05585632Phase 1
• A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1
• Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult SubjectsCompletedNCT03345043Phase 1
• Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult SubjectsCompletedNCT03076385Phase 1